Immucor To Respond To FDA Notice
Published: 26-Jun-2009
Company has 10 working days to respond to FDA' action and 30 days to submit remediation plan
FDA has issued a notice of intent to Immucor to revoke its biologics license, with respect to its Reagent Red Blood Cells and Anti-E Blood Grouping Reagent product.
As per FDA' letter, the company has 10 working days to respond to FDA' administrative action and 30 days to submit a remediation plan. The company will use the extensive remediation work already underway and documented in detail, to FDA to facilitate its response.
Dr De Chirico, President and CEO, Immucor, said: We take our regulatory responsibilities very seriously. We have been working diligently to improve our quality systems and processes, including the deficiencies identified by the FDA, with Our Quality Process Improvement Project. We are committed to completing this Project as quickly as possible.
During its fiscal third quarter of 2009, the company formalized efforts to improve its quality systems through the 'Quality Process Improvement Project'.
Dr. De Chirico added: We have kept the FDA informed of the Project's objectives and progress by providing written updates to them on a monthly basis that detail our plans for corrective actions as well as the implementation of the correction action plans to prevent recurrence. The FDA has acknowledged that they are aware of our efforts to correct their identified deficiencies, but the letter indicates the FDA's action is based on their January 2009 inspection. The FDA has not performed an inspection since January 2009.
Network Sites

Suppliers To This Sector
Browse A-Z
Almac
Drug Development Solutions ...
STARLIMS
Benefits for Life Science Labs ...
Parenteral Drug Association (PDA)
Pharmaceutical Information and Education Services ...
Burkert Fluid Control Systems
Fluid and Gas Control Systems ...
IMCOR
LIMS and Laboratory Informatics Consultancy ...
Umicore Precious Metals Chemistry
Chemicals and Catalysts for Industrial Applications ...
White Papers
Browse A-Z
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
A Vaccinne Bioassay Case Study – A Successful Strategic Outsourcing Model
Increasingly, pharma and biotech firms are searching for new drivers of revenue and profit ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
Enabling Drug Delivery Deal Making
Transdermal drug delivery: Time for a closer look. To find out more download this free whi ...
Automating Training Control Processes to Comply with FDA Requirements
Well-managed training programs minimize the risk of non-compliance and improve product qua ...
TNO Pharma Services: From Discovery to the Clinic
Our kinetics & metabolism experts can help you select and further develop your candidate d ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully